CS
BVS icon

Credit Suisse’s Bioventus BVS Stock Holding History

Credit Suisse’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,937
Closed -$57.3K – 3329
2022
Q4 		$57.3K Sell
21,937
-246
-1% -$1.07K ﹤0.01% 3399
2022
Q3 		$156K Buy
22,183
+149
+0.7% +$1.17K ﹤0.01% 3323
2022
Q2 		$150K Buy
+22,034
New +$225K ﹤0.01% 3426

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Credit Suisse's BVS Position: Q1 2023 in Review

Credit Suisse sold out of Bioventus (BVS) in Q1 2023, closing a stake of 21,937 shares — an estimated $57.3K sold.

Credit Suisse first reported a position in BVS in Q2 2022 and held it in 3 quarters. The position peaked at $156K in Q3 2022. 71 funds tracked by Wall St. Rank hold BVS as of Q1 2023.

  • Credit Suisse reported no remaining Bioventus position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 21,937 Bioventus shares in Q1 2023, an estimated $57.3K.
  • Credit Suisse first reported a position in Bioventus in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Bioventus position peaked at $156K in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Bioventus as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.